Tuesday, September 24, 2024
11:00 AM Eastern Daylight Time
The supply chain for mRNA-based cell and gene therapies presents unique challenges due to the sensitive nature of these products. And, as mRNA technology continues to advance, robust processes and scalable solutions are necessary to meet increasing demand. Compliance with regulatory guidelines, development of end-to-end GMP facilities, investment in sustainable cold chain management, and more, are all necessary to ensure supply chain efficiency.
